Phase 2
Completed N=41
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Source: ClinicalTrials.gov NCT01371305 ↗
Enrolled (actual)
41
Serious AEs
9.8%
Results posted
Feb 2020
Primary outcomePrimary: Number of Participants With Adverse Events (AEs) — 6; 5; 6; 4 Participants
Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneously (SC) administered multiple, escalating doses of BG00011 (a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin, formerly known as STX-100) in participants with IPF. The Secondary objectives are to estimate the pharmacokinetic (PK) parameters after the 1st dose and after the last dose of multiple, escalating doses of BG00011 in participants with IPF, to assess the immunogenicity of BG00011 in participants with IPF, and to assess the effect of BG00011 on biomarkers isolated from bronchoalveolar lavage (BAL) and peripheral blood in participants with IPF.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events (AEs) |
6; 5; 6; 4; 6; 7 | — |
| SECONDARY Time to Reach Maximum Observed Serum Concentration (Tmax) of BG00011 |
168; 101; 132; 134; 96.4; 42.7 | — |
| SECONDARY Maximum Observed Serum Concentration (Cmax) of BG00011 |
71.3; 335; 716; 4370; 12900; 134 | — |
| SECONDARY Area Under the Serum Concentration Time Curve From Time 0 to Last Quantifiable Observed Concentration AUC(0-t) of BG00011 |
9200; 44800; 92600; 513000; 1730000; 44600 | — |
| SECONDARY Area Under the Serum Concentration-Time Curve From Time 0 to 168 Hours AUC(0-168) of BG00011 |
9200; 44800; 92600; 497000; 1690000; 21000 | — |
| SECONDARY Apparent Terminal Elimination Half Life (T1/2) of BG00011 |
178; 177; 168; 178; 250 | — |
| SECONDARY Apparent Terminal Rate Constant [λz] |
0.00390; 0.00508; 0.00442; 0.00423; 0.00286 | — |
| SECONDARY Area Under the Concentration Versus Time Curve From Time Zero to Infinity AUC(0-inf) of BG00011 |
41900; 362000; 1190000; 7250000; 24300000 | — |
| SECONDARY Apparent Clearance (CL/F) of BG00011 |
0.913; 0.758; 0.801; 0.501; 0.486 | — |
| SECONDARY Apparent Volume of Distribution (Vd/F) of BG00011 |
234; 183; 183; 120; 168 | — |
| SECONDARY Percentage Change (PC) From Baseline in Biomarkers Isolated From Bronchoalveolar Lavage (BAL) |
4.39; -0.25; -5.16; -51.07; -70.90; -7.87 | — |
| SECONDARY Number of Participants With Treatment Emergent Antibodies to BG00011 |
1; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Key Inclusion Criteria
- Clinical features consistent with IPF prior to screening (based on the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) consensus criteria for the diagnosis of IPF).
- Forced (expiratory) Vital Capacity (FVC) ≥ 50% of predicted value.
- DLco (corrected for hemoglobin) ≥ 30% predicted value.
- Oxygen saturation > 90% at rest by pulse oximetry while breathing ambient air or receiving ≤2 L/minute of supplemental oxygen.
- Residual volume ≤ 120% predicted value.
- Ratio of Forced Expiratory Volume over 1 second (FEV1) to FVC ≥ 0.65 after the use of a bronchodilator.
- Other known causes of interstitial lung disease have been excluded (e.g., drug toxicities, environmental exposures, connective tissue diseases).
- High Resolution Computed Tomography (HRCT) image fulfills the criteria for 'Usual Interstitial Pneumonia (UIP) pattern'.
- If the HRCT image does not fulfill the criteria for 'UIP pattern' a surgical lung biopsy is necessary for the diagnosis of IPF (lung biopsy performed prior to screening is acceptable). If a lung biopsy has been performed, it must fulfill the histopathological criteria for either 'UIP pattern' or 'probable UIP pattern' with the appropriate HRCT correlate.
- Adequate bone marrow and liver function.
- Patient has a life expectancy of at least 12 months.
Key Exclusion Criteria
- Findings that are diagnostic of a condition other than UIP on surgical lung biopsy (performed either before or after screening), HRCT imaging, transbronchial lung biopsy, or bronchoalveolar lavage (BAL).
- Serious local infection or systemic infection within 3 months prior to screening.
- Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 4 weeks of initial screening.
- Currently receiving high dose corticosteroid, cytotoxic therapy (e.g., chlorambucil, azathioprine, cyclophosphamide, methotrexate), nintedanib (Ofev®), vasodilator therapy for pulmonary hypertension (e.g., bosentan), unapproved and/or investigational therapy for IPF or administration of such therapeutics within 5 half-lives of the agent prior to initial screening in this study.
- End-stage fibrotic disease requiring organ transplantation within 6 months
NOTE: Other protocol defined Inclusion/Exclusion Criteria may apply.
Data sourced from ClinicalTrials.gov (NCT01371305). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.